Reviva Pharmaceuticals (NASDAQ:RVPH) Upgraded to Strong-Buy by EF Hutton Acquisition Co. I

Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by investment analysts at EF Hutton Acquisition Co. I to a “strong-buy” rating in a report issued on Monday, Zacks.com reports.

A number of other equities analysts have also issued reports on RVPH. Maxim Group reaffirmed a “hold” rating on shares of Reviva Pharmaceuticals in a research report on Friday, August 16th. Benchmark reissued a “speculative buy” rating and issued a $17.00 price target on shares of Reviva Pharmaceuticals in a report on Monday, August 26th. Finally, HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of Reviva Pharmaceuticals in a report on Thursday, July 11th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Reviva Pharmaceuticals presently has an average rating of “Buy” and an average target price of $14.33.

Reviva Pharmaceuticals Trading Up 3.2 %

Shares of RVPH stock opened at $1.28 on Monday. Reviva Pharmaceuticals has a 1 year low of $0.60 and a 1 year high of $6.80. The firm’s fifty day simple moving average is $1.07 and its 200 day simple moving average is $1.85. The firm has a market capitalization of $38.17 million, a P/E ratio of -0.81 and a beta of -0.10.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its earnings results on Wednesday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02. Equities research analysts anticipate that Reviva Pharmaceuticals will post -0.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Reviva Pharmaceuticals

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Vanguard Group Inc. lifted its position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 2.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 1,001,836 shares of the company’s stock after purchasing an additional 26,854 shares during the quarter. Vanguard Group Inc. owned 3.59% of Reviva Pharmaceuticals worth $3,787,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.